Copyright
©The Author(s) 2022.
World J Gastrointest Oncol. Sep 15, 2022; 14(9): 1785-1797
Published online Sep 15, 2022. doi: 10.4251/wjgo.v14.i9.1785
Published online Sep 15, 2022. doi: 10.4251/wjgo.v14.i9.1785
Variables | |
Sex, n (%) | |
Male | 7 (46.7) |
Female | 8 (53.3) |
Age (yr) | 55.53 ± 7.89 |
Body mass index, kg/m2 | 22.29 ± 2.94 |
Resectability, n (%) | |
Borderline resectable (n) | 7 (46.7) |
Advanced pancreatic cancer (n) | 8 (53.3) |
ASA grade, n (%) | |
I | 13 (86.7) |
II | 2 (13.3) |
Chemotherapy regimen, n (%) | |
AG | 13 (86.7) |
Modified FOLFIRINOX | 2 (13.3) |
ECOG score, n (%) | |
0 | 11 (73.3) |
1 | 2 (13.35) |
2 | 2 (13.35) |
Chemotherapy cycle | 4 ± 1 |
Response to chemotherapy | |
PR | 15 (100%) |
CR | 0 |
Tumor diameter before chemotherapy (cm) | 4.17 ± 1.40 |
Tumor diameter before surgery (cm) | 3.03 ± 1.13 |
Tumor regression (%) | 28.40 ± 9.71 |
CA19-9 level before chemotherapy (U/mL) | 736.25 (8.44-1200.00)1 |
CA19-9 level before surgery (U/mL) | 51.85 (4.81-341.3)1 |
Decrease in CA19-9 level (%) | 57.07 ± 32.07 |
Total count of CTCs before chemotherapy (n) | 16 (13-26)1 |
Total count of CTCs before surgery (n) | 7.13 ± 2.88 |
Decrease in the total number of CTCs (%) | 65.33 ± 12.09 |
- Citation: He YG, Huang XB, Li YM, Li J, Peng XH, Huang W, Tang YC, Zheng L. Efficacy and safety of laparoscopic radical resection following neoadjuvant therapy for pancreatic ductal adenocarcinoma: A retrospective study. World J Gastrointest Oncol 2022; 14(9): 1785-1797
- URL: https://www.wjgnet.com/1948-5204/full/v14/i9/1785.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v14.i9.1785